Healthcare Review: Celsion Corporation, ISIS Pharmaceuticals, BioCryst Pharmaceuticals, Petmed, Catalyst Pharmaceutical Print E-mail
By Staff and Wire Reports   
Monday, 22 July 2013 12:58
U.S. stocks rose, amid monthly flows into equity exchange-traded funds that are at a five-year high, as housing data and earnings from companies including McDonald’s Corp. fueled speculation monetary stimulus would continue. Data today showed purchases of previously owned houses fell 1.2 percent to a 5.08 million annualized rate last month, according to the National Association of Realtors. The median forecast of 79 economists surveyed by Bloomberg called for a 5.26 million pace.

Celsion Corporation (NASDAQ:CLSN) shares dropped 4.94% to $1.35. CLSN and Zhejiang Hisun Pharmaceutical Company Ltd. (SSE Code: 600267), a leading Chinese pharmaceutical company, on July 19 announced that they have entered into a Memorandum of Understanding to pursue ongoing collaborations for the continued clinical development of ThermoDox as well as the technology transfer relating to the commercial manufacture of ThermoDox for the greater China territory.

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) shares dropped 4.64% to $29.61. The company on July 22 announced data from a Phase 2 study of ISIS-APOCIII(Rx) in patients with high to severely high triglycerides on stable doses of fibrates. In this study, patients treated with ISIS-APOCIII(Rx) experienced reductions of up to 70 percent in apolipoprotein C-III (apoC-III) and up to 64 percent in triglycerides. In addition, patients treated with ISIS-APOCIII(Rx) experienced an up to 52 percent increase in high-density lipoprotein cholesterol (HDL-C), the 'good' cholesterol, and an up to 77 percent reduction in apoC-III-associated very low-density lipoprotein (VLDL) particles.

Isis is also evaluating ISIS-APOCIII(Rx) in this Phase 2 study as a monotherapy in patients with severely high triglycerides and plans to report these data at the European Society of Cardiology on August 31 in Amsterdam.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares increased 25.16% to $3.08. The company, on July 22, announced that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administered BCX4161 in healthy volunteers successfully met all of its objectives. The safety, tolerability, drug exposure and on-target kallikrein inhibition results of this Phase 1 trial strongly support advancing the development program into a Phase 2a study in hereditary angioedema (HAE) patients.

Petmed Express Inc (NASDAQ:PETS) shares jumped 12.53% to $17. The company on July 22 reported that its first-quarter net income was $4.8 million, or $0.24 per share, up from $4.0 million, or $0.20 per share in the year ago quarter. Net sales for the quarter were $74.2 million, compared to $69.0 million last year, an increase of 7.6%. Analysts expected the company to report earnings of $0.22 per share and revenues of $69.85 million for the quarter.

Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) shares gained 9.58% to $1.32 on no official news. The company on June 27 provided an update on its progress with its lead investigational product, FIRDAPSETM.

"Over the past six months, we have made great strides in our advancement of Firdapse for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). We have recently achieved several important milestones in our development plan, and we therefore feel that this is an appropriate time to report our progress to investors and other stakeholders," said Patrick J. McEnany, Chief Executive Officer of Catalyst Pharmaceutical Partners, Inc.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter